SlideShare a Scribd company logo
1 of 18
Download to read offline
1




Earnings Release 2Q08
Highlights For The Period                                                                      2



• A growth of 21.8% of the consolidated Gross Revenue when compared to the same
period of the previous year, having reached R$ 742.8 million.


• The adjusted EBITDA was of R$ 23.9 million, a growth of 21.6% in relation to the one
registered in the 2Q07 of R$ 19.7 million.


• Profarma’s market share reached 11.8% in the 2Q08. 1.1 percentage point above the
one reached during the same period of the previous year.


• Profarma contracted the services of UBS Pactual S.A. bank, on May 29, 2008, to be the
market maker of its shares in order to promote their liquidity.


• Profarma opened on July, 14, 2008 its first exclusive distribution center for the hospital
and vaccine segment in São Paulo.
Gross Revenues Evolution                         3




                                           In R$ MM




                                   742.8
                           702.6

                609.7




                2Q07       1Q08    2Q08
Gross Revenues Breakdown                                                       4




                                                                         In R$ MM




   (R$ Million)                 2Q08    2Q07    Chg. %   1Q08    Chg.%
   Branded                      519.7   404.7   28.4%    503.0    3.3%
   Generics                     42.6    35.6    19.6%    34.0    25.4%
   OTC                          131.7   120.2    9.5%    119.5   10.2%
   Health and Beauty Products   29.3    36.7    -20.1%   31.0    -5.5%
   Other                        19.6    12.5    57.1%    15.1    29.3%
   Total                        742.8   609.7   21.8%    702.6    5.7%
Market Share (%)                                             5




                                11.5           11.8   11.8
                                       10.7
           9.6            9.6
    9.3




   2004   2005           2006   2007   2T07   1T08    2T08


           Source: IMS
Gross Profit and Revenues                                                                                     6
from Services to Suppliers



                                                                                                   In R$ MM
                                                                        10.8%                and as % Net Revenues
                      10.7%

                                                  10.4%

                                                                        10.5
                                                  7.4
                      7.0



                                                  55.7                  58.9
                      50.0




                      2Q07                       1Q08                   2Q08


             Gross Profit     Revenues from Services to Suppliers   Adjusted GP Margin (%)
Operating Expenses                                                                                                   7




                         7.9%                                               7.9%                          In R$ MM
                                                                                                    and as % Net Revenues
                                                  7.8%

                                                                           50.9
                                                 47.5
                        42.0




                        2Q07                      1Q08                     2Q08


        EXPENSES: General and Administrative + Selling and Marketing + Logistics and Distribution
Net Financial Expenses                                  8




                                             In R$ MM
                                1.4%   and as % Net Revenues

                         0.9%
                0.5%
                                9.1




                         5.6



                2.8




                2Q07     1Q08   2Q08
Net Income                                         9




             1.6%                       In R$ MM
                                  and as % Net Revenues
                           1.0%

                    0.8%
             8.3

                           6.6

                    5.0




             2Q07   1Q08   2Q08
Adjusted EBITDA and EBITDA Margin                          10




                                                 In R$ MM
               3.7%                 3.7%   and as % Net Revenues



                            3.1%
                                    23.9

               19.7
                           18.6




              2Q07         1Q08     2Q08
Cash Flow                                                                                                11




(R$ Million)                                           2Q08     2Q07       Chg. %     1Q08      Chg. %

Cash Flow (Used) / Generated in Operating Activities   (24.0)   (67.1)     64.3%        5.7    -521.1%
 Internal Cash Generation                               16.7     17.1      -2.0%       14.8      13.4%
 Operating Assets Variation                            (40.7)   (84.2)     51.7%       (9.1)   -349.1%
     Trade Note Receivable                             (11.6)   (22.4)     48.4%       29.9    -138.7%
     Inventories                                        (0.3)   (41.3)     99.3%       19.3    -101.5%
     Suppliers                                          (4.2)    (8.9)     52.9%      (49.4)    91.5%
     Other Items                                       (24.6)   (11.6)    -112.6%      (8.8)   -179.8%

Cash Flow (Used) in Investing Activities                (3.1)    (1.2)    -154.1%      (2.1)   -45.6%

Cash Flow (Used) / Generated by Financing Activities   38.5      (0.0)   -154232.0%   (34.4)   -212.1%

Net Increase (Decrease) in Cash                        11.5     (68.4)    -116.8%     (30.8)   -137.3%
Cash Cycle                                                                                             12




                                               3Q06   4Q06   1Q07   2Q07   3Q07   4Q07   1Q08   2Q08

           Cash Cycle - Days *                 49.3   53.4   62.5   69.6   67.8   64.3   68.8   67.2
Accounts Receivable (1)                        45.2   50.0   54.6   53.1   50.9   51.7   50.7   49.2
Inventories (2)                                33.1   44.7   43.4   47.2   41.3   48.6   47.9   45.7
Accounts Payable (3)                           29.0   41.3   35.6   30.7   24.5   36.0   29.8   27.7


*Average
(1) Average of Gross Revenues in the Quarter
(2) Average of COGS in the Quarter
(3) Average of COGS in the Quarter
Indebtedness                                                                             13




                                                                                  In R$ MM
                                Net Debt (R$ MM) and Net Debt / Ebitda*



                                                  1.5                     1.9
                          0.9

                                                                          163.3

                                                 124.8


                         68.6




                         2Q07                    1Q08                     2Q08


         * Ebitda = Accumulated last 12 months
Capex                                        14




                                   In R$ MM
                             and as % Net Revenues
        0.2%          0.5%
               0.3%



                      3.1


               2.1


        1.2




        2Q07   1Q08   2Q08
Operating Indicators                                                                  15




                   Service Level                         Logistics E.P.M
          (units served / units requested)              (Errors per Million)




                                        92.8%

                                                204.3

  92.0%



                     91.2%                                    100.0            98.0




  2Q07                1Q08               2Q08   2Q07          1Q08             2Q08
Share Performance                                                                                                                                                                                                                 16


196         * 100 pts basis on 25/oct/2006
191

186

181

176

171

166

161
                                                                                                                                                                                                                                      164
156

151

146

141

136                                                                                                                                                                                                                                   139
131

126

121

116

111
                                                                                                                                                                                                                                      110
106

101

 96
      25-    9- 24- 9- 24-     8-   23-    7-   22- 9- 24-     8-   23-    8-   23-    7-   22-   7-    22-    6- 21-    5-   20-    5-   20-    4- 19- 4- 19-     3-   18-    2-   17- 3- 18-     2-   17-    2-   17-    1-   16-    30-
      out   nov nov dez dez   jan   jan   fev   fev mar mar   abr   abr   mai   mai   jun   jun   jul   jul   ago ago   set   set   out   out   nov nov dez dez   jan   jan   fev   fev mar mar   abr   abr   mai   mai   jun   jun    jun



                                                                                            Ibovespa                    IGC               Profarma
Analyst Coverage                                                                          17




            Firm                            Analyst                      Recommendation

                           João Carlos dos Santos - Alexandre Pizano
                                55 11 2188-4282 / 4316 / 4024
        Merril Lynch                                                          Buy
                                  joaocarlos_santos@ml.com
                                  alexandre_pizano@ml.com


                          Tufic Salem - Rafael Shin - Antonio Gonzalez
                                52 55 5283-8952 / 8969 / 3821
        Credit Suisse            tufic.salem@credit-suisse.com                Buy
                                 rafael.shin@credit-suisse.com
                               antonio.gonzalez@creditsuisse.com

                                         Alan Cardoso
      Prosper Corretora             Fone: 55 21 2138-8465                     Buy
                              alan.cardoso@bancoprosper.com.br

                                 Renata Faber - Marcio Osako
                                Fone: 55 11 5029-4542 / 4650                  Hold
         Itau BBA
                                  renata.faber@itau.com.br
                                  marcio.osako@itau.com.br
18




             IR Contacts:

             Max Fischer
             CFO and IRO

              Beatriz Diez
           IR Coordenator


 Phone.: 55 (21) 4009 0276
E-mail: ri@profarma.com.br
   www.profarma.com.br/ir

More Related Content

What's hot

Ernings Release 4 Q08
Ernings Release 4 Q08Ernings Release 4 Q08
Ernings Release 4 Q08Profarma
 
Profarma 1Q10
Profarma 1Q10Profarma 1Q10
Profarma 1Q10Profarma
 
omnicom group Q3 2008 Investor Presentation
omnicom group  Q3 2008 Investor Presentationomnicom group  Q3 2008 Investor Presentation
omnicom group Q3 2008 Investor Presentationfinance22
 
2008 - Second Quarter 2008 Results
2008 - Second Quarter 2008 Results2008 - Second Quarter 2008 Results
2008 - Second Quarter 2008 ResultsEmbraer RI
 
Verizon 4Q 2008 earnings report
Verizon 4Q 2008 earnings reportVerizon 4Q 2008 earnings report
Verizon 4Q 2008 earnings reportearningsreport
 
Wessanen q3 2012 press release
Wessanen q3 2012 press releaseWessanen q3 2012 press release
Wessanen q3 2012 press releaseKlaus Arntz
 
Profarma apresentação 3 q11 final
Profarma apresentação 3 q11 finalProfarma apresentação 3 q11 final
Profarma apresentação 3 q11 finalProfarma
 
Apresentação 1 q12 eng-1
Apresentação 1 q12 eng-1Apresentação 1 q12 eng-1
Apresentação 1 q12 eng-1Localiza
 

What's hot (10)

Apresentacao Call Result 1 T08 Eng Final
Apresentacao Call Result 1 T08 Eng FinalApresentacao Call Result 1 T08 Eng Final
Apresentacao Call Result 1 T08 Eng Final
 
Ernings Release 4 Q08
Ernings Release 4 Q08Ernings Release 4 Q08
Ernings Release 4 Q08
 
Profarma 1Q10
Profarma 1Q10Profarma 1Q10
Profarma 1Q10
 
omnicom group Q3 2008 Investor Presentation
omnicom group  Q3 2008 Investor Presentationomnicom group  Q3 2008 Investor Presentation
omnicom group Q3 2008 Investor Presentation
 
2008 - Second Quarter 2008 Results
2008 - Second Quarter 2008 Results2008 - Second Quarter 2008 Results
2008 - Second Quarter 2008 Results
 
Verizon 4Q 2008 earnings report
Verizon 4Q 2008 earnings reportVerizon 4Q 2008 earnings report
Verizon 4Q 2008 earnings report
 
Wessanen q3 2012 press release
Wessanen q3 2012 press releaseWessanen q3 2012 press release
Wessanen q3 2012 press release
 
Profarma apresentação 3 q11 final
Profarma apresentação 3 q11 finalProfarma apresentação 3 q11 final
Profarma apresentação 3 q11 final
 
Investors meeting 1 q08 results
Investors meeting   1 q08 resultsInvestors meeting   1 q08 results
Investors meeting 1 q08 results
 
Apresentação 1 q12 eng-1
Apresentação 1 q12 eng-1Apresentação 1 q12 eng-1
Apresentação 1 q12 eng-1
 

Viewers also liked

Conference Call 3Q14
Conference Call 3Q14Conference Call 3Q14
Conference Call 3Q14Profarma
 
Earnings Release 4Q08 Presentation
Earnings Release 4Q08 PresentationEarnings Release 4Q08 Presentation
Earnings Release 4Q08 PresentationProfarma
 
Earnings Release 2Q08 Presentation
Earnings Release 2Q08 PresentationEarnings Release 2Q08 Presentation
Earnings Release 2Q08 PresentationProfarma
 
Earnings Release 1Q09 Presentation
Earnings Release 1Q09 PresentationEarnings Release 1Q09 Presentation
Earnings Release 1Q09 PresentationProfarma
 
Profarma Apresentação 3Q10
Profarma Apresentação 3Q10Profarma Apresentação 3Q10
Profarma Apresentação 3Q10Profarma
 
Earnings Release 3 Q08
Earnings Release 3 Q08Earnings Release 3 Q08
Earnings Release 3 Q08Profarma
 
Earnings Release 3Q07 Presentation
Earnings Release 3Q07 PresentationEarnings Release 3Q07 Presentation
Earnings Release 3Q07 PresentationProfarma
 
Profarma apresentação 2 q11
Profarma apresentação 2 q11Profarma apresentação 2 q11
Profarma apresentação 2 q11Profarma
 

Viewers also liked (8)

Conference Call 3Q14
Conference Call 3Q14Conference Call 3Q14
Conference Call 3Q14
 
Earnings Release 4Q08 Presentation
Earnings Release 4Q08 PresentationEarnings Release 4Q08 Presentation
Earnings Release 4Q08 Presentation
 
Earnings Release 2Q08 Presentation
Earnings Release 2Q08 PresentationEarnings Release 2Q08 Presentation
Earnings Release 2Q08 Presentation
 
Earnings Release 1Q09 Presentation
Earnings Release 1Q09 PresentationEarnings Release 1Q09 Presentation
Earnings Release 1Q09 Presentation
 
Profarma Apresentação 3Q10
Profarma Apresentação 3Q10Profarma Apresentação 3Q10
Profarma Apresentação 3Q10
 
Earnings Release 3 Q08
Earnings Release 3 Q08Earnings Release 3 Q08
Earnings Release 3 Q08
 
Earnings Release 3Q07 Presentation
Earnings Release 3Q07 PresentationEarnings Release 3Q07 Presentation
Earnings Release 3Q07 Presentation
 
Profarma apresentação 2 q11
Profarma apresentação 2 q11Profarma apresentação 2 q11
Profarma apresentação 2 q11
 

Similar to Earnings Release 2Q08 Presentation

Earnings Release 1Q08 Presentation
Earnings Release 1Q08 PresentationEarnings Release 1Q08 Presentation
Earnings Release 1Q08 PresentationProfarma
 
arnings Release 2Q07 Presentation
arnings Release 2Q07 Presentationarnings Release 2Q07 Presentation
arnings Release 2Q07 PresentationProfarma
 
Earnings Release 3Q08 Presentation
Earnings Release 3Q08 PresentationEarnings Release 3Q08 Presentation
Earnings Release 3Q08 PresentationProfarma
 
Earnings Release 1Q07 Presentation
Earnings Release 1Q07 PresentationEarnings Release 1Q07 Presentation
Earnings Release 1Q07 PresentationProfarma
 
Earnings Release 4 Q07
Earnings Release 4 Q07Earnings Release 4 Q07
Earnings Release 4 Q07Profarma
 
Earnings Release 4Q07 Presentation
Earnings Release 4Q07 PresentationEarnings Release 4Q07 Presentation
Earnings Release 4Q07 PresentationProfarma
 
Profarma apresentacao 1_q11
Profarma apresentacao 1_q11Profarma apresentacao 1_q11
Profarma apresentacao 1_q11Profarma
 
Profarma apresentacao 1_q11
Profarma apresentacao 1_q11Profarma apresentacao 1_q11
Profarma apresentacao 1_q11Profarma
 
Profarma 4 q12
Profarma 4 q12Profarma 4 q12
Profarma 4 q12Profarma
 
Profarma apresentação 1 q10 final
Profarma apresentação 1 q10 finalProfarma apresentação 1 q10 final
Profarma apresentação 1 q10 finalProfarma
 
Earnings Release 2Q09 Presentation
Earnings Release 2Q09 PresentationEarnings Release 2Q09 Presentation
Earnings Release 2Q09 PresentationProfarma
 
Profarma 4Q10
Profarma 4Q10Profarma 4Q10
Profarma 4Q10Profarma
 
Profarma 4Q10
Profarma 4Q10Profarma 4Q10
Profarma 4Q10Profarma
 
Profarma 1Q12
Profarma 1Q12Profarma 1Q12
Profarma 1Q12Profarma
 
Conference Call Presentation 4Q09
Conference Call Presentation 4Q09Conference Call Presentation 4Q09
Conference Call Presentation 4Q09Tempo
 
Earnings Release 3Q09 Presentation
Earnings Release 3Q09 PresentationEarnings Release 3Q09 Presentation
Earnings Release 3Q09 PresentationProfarma
 
Profarma apresentação 2 q10 final
Profarma apresentação 2 q10 finalProfarma apresentação 2 q10 final
Profarma apresentação 2 q10 finalProfarma
 
Profarma 3Q10
Profarma 3Q10Profarma 3Q10
Profarma 3Q10Profarma
 
Profarma 3Q12
Profarma 3Q12Profarma 3Q12
Profarma 3Q12Profarma
 

Similar to Earnings Release 2Q08 Presentation (19)

Earnings Release 1Q08 Presentation
Earnings Release 1Q08 PresentationEarnings Release 1Q08 Presentation
Earnings Release 1Q08 Presentation
 
arnings Release 2Q07 Presentation
arnings Release 2Q07 Presentationarnings Release 2Q07 Presentation
arnings Release 2Q07 Presentation
 
Earnings Release 3Q08 Presentation
Earnings Release 3Q08 PresentationEarnings Release 3Q08 Presentation
Earnings Release 3Q08 Presentation
 
Earnings Release 1Q07 Presentation
Earnings Release 1Q07 PresentationEarnings Release 1Q07 Presentation
Earnings Release 1Q07 Presentation
 
Earnings Release 4 Q07
Earnings Release 4 Q07Earnings Release 4 Q07
Earnings Release 4 Q07
 
Earnings Release 4Q07 Presentation
Earnings Release 4Q07 PresentationEarnings Release 4Q07 Presentation
Earnings Release 4Q07 Presentation
 
Profarma apresentacao 1_q11
Profarma apresentacao 1_q11Profarma apresentacao 1_q11
Profarma apresentacao 1_q11
 
Profarma apresentacao 1_q11
Profarma apresentacao 1_q11Profarma apresentacao 1_q11
Profarma apresentacao 1_q11
 
Profarma 4 q12
Profarma 4 q12Profarma 4 q12
Profarma 4 q12
 
Profarma apresentação 1 q10 final
Profarma apresentação 1 q10 finalProfarma apresentação 1 q10 final
Profarma apresentação 1 q10 final
 
Earnings Release 2Q09 Presentation
Earnings Release 2Q09 PresentationEarnings Release 2Q09 Presentation
Earnings Release 2Q09 Presentation
 
Profarma 4Q10
Profarma 4Q10Profarma 4Q10
Profarma 4Q10
 
Profarma 4Q10
Profarma 4Q10Profarma 4Q10
Profarma 4Q10
 
Profarma 1Q12
Profarma 1Q12Profarma 1Q12
Profarma 1Q12
 
Conference Call Presentation 4Q09
Conference Call Presentation 4Q09Conference Call Presentation 4Q09
Conference Call Presentation 4Q09
 
Earnings Release 3Q09 Presentation
Earnings Release 3Q09 PresentationEarnings Release 3Q09 Presentation
Earnings Release 3Q09 Presentation
 
Profarma apresentação 2 q10 final
Profarma apresentação 2 q10 finalProfarma apresentação 2 q10 final
Profarma apresentação 2 q10 final
 
Profarma 3Q10
Profarma 3Q10Profarma 3Q10
Profarma 3Q10
 
Profarma 3Q12
Profarma 3Q12Profarma 3Q12
Profarma 3Q12
 

More from Profarma

Profarma Day - 13.12.2017
Profarma Day - 13.12.2017Profarma Day - 13.12.2017
Profarma Day - 13.12.2017Profarma
 
Apresentação 3Q17
Apresentação 3Q17Apresentação 3Q17
Apresentação 3Q17Profarma
 
Apresentação 3T17
Apresentação 3T17Apresentação 3T17
Apresentação 3T17Profarma
 
Apresentação 2Q17
Apresentação 2Q17Apresentação 2Q17
Apresentação 2Q17Profarma
 
Apresentação 2T17
Apresentação 2T17Apresentação 2T17
Apresentação 2T17Profarma
 
Apresentação 1Q17
Apresentação 1Q17Apresentação 1Q17
Apresentação 1Q17Profarma
 
Apresentação 1T17
Apresentação 1T17Apresentação 1T17
Apresentação 1T17Profarma
 
4Q16 Presentation
4Q16 Presentation4Q16 Presentation
4Q16 PresentationProfarma
 
Apresentação 4T16
Apresentação 4T16Apresentação 4T16
Apresentação 4T16Profarma
 
Profarma - 3Q16 earnings release
Profarma - 3Q16 earnings releaseProfarma - 3Q16 earnings release
Profarma - 3Q16 earnings releaseProfarma
 
Profarma - Divulgação de resultados 3T16
Profarma - Divulgação de resultados 3T16Profarma - Divulgação de resultados 3T16
Profarma - Divulgação de resultados 3T16Profarma
 
Profarma Aquisição Rosario
Profarma Aquisição Rosario Profarma Aquisição Rosario
Profarma Aquisição Rosario Profarma
 
Profarma Rosario Chain Acquisition
Profarma Rosario Chain AcquisitionProfarma Rosario Chain Acquisition
Profarma Rosario Chain AcquisitionProfarma
 
Profarma - 2Q16
Profarma - 2Q16Profarma - 2Q16
Profarma - 2Q16Profarma
 
Profarma - 2T16
Profarma - 2T16Profarma - 2T16
Profarma - 2T16Profarma
 
Profarma reunião pública vf
Profarma reunião pública vfProfarma reunião pública vf
Profarma reunião pública vfProfarma
 
Profarma Reunião Pública 2016
Profarma Reunião Pública 2016Profarma Reunião Pública 2016
Profarma Reunião Pública 2016Profarma
 
1 t16 varejo
1 t16 varejo1 t16 varejo
1 t16 varejoProfarma
 

More from Profarma (20)

Profarma Day - 13.12.2017
Profarma Day - 13.12.2017Profarma Day - 13.12.2017
Profarma Day - 13.12.2017
 
Apresentação 3Q17
Apresentação 3Q17Apresentação 3Q17
Apresentação 3Q17
 
Apresentação 3T17
Apresentação 3T17Apresentação 3T17
Apresentação 3T17
 
Apresentação 2Q17
Apresentação 2Q17Apresentação 2Q17
Apresentação 2Q17
 
Apresentação 2T17
Apresentação 2T17Apresentação 2T17
Apresentação 2T17
 
Apresentação 1Q17
Apresentação 1Q17Apresentação 1Q17
Apresentação 1Q17
 
Apresentação 1T17
Apresentação 1T17Apresentação 1T17
Apresentação 1T17
 
4Q16 Presentation
4Q16 Presentation4Q16 Presentation
4Q16 Presentation
 
Apresentação 4T16
Apresentação 4T16Apresentação 4T16
Apresentação 4T16
 
Profarma - 3Q16 earnings release
Profarma - 3Q16 earnings releaseProfarma - 3Q16 earnings release
Profarma - 3Q16 earnings release
 
Profarma - Divulgação de resultados 3T16
Profarma - Divulgação de resultados 3T16Profarma - Divulgação de resultados 3T16
Profarma - Divulgação de resultados 3T16
 
Profarma Aquisição Rosario
Profarma Aquisição Rosario Profarma Aquisição Rosario
Profarma Aquisição Rosario
 
Profarma Rosario Chain Acquisition
Profarma Rosario Chain AcquisitionProfarma Rosario Chain Acquisition
Profarma Rosario Chain Acquisition
 
Profarma - 2Q16
Profarma - 2Q16Profarma - 2Q16
Profarma - 2Q16
 
Profarma - 2T16
Profarma - 2T16Profarma - 2T16
Profarma - 2T16
 
Profarma reunião pública vf
Profarma reunião pública vfProfarma reunião pública vf
Profarma reunião pública vf
 
Profarma Reunião Pública 2016
Profarma Reunião Pública 2016Profarma Reunião Pública 2016
Profarma Reunião Pública 2016
 
1 t16 varejo
1 t16 varejo1 t16 varejo
1 t16 varejo
 
1 q16
1 q161 q16
1 q16
 
4 t15
4 t154 t15
4 t15
 

Earnings Release 2Q08 Presentation

  • 2. Highlights For The Period 2 • A growth of 21.8% of the consolidated Gross Revenue when compared to the same period of the previous year, having reached R$ 742.8 million. • The adjusted EBITDA was of R$ 23.9 million, a growth of 21.6% in relation to the one registered in the 2Q07 of R$ 19.7 million. • Profarma’s market share reached 11.8% in the 2Q08. 1.1 percentage point above the one reached during the same period of the previous year. • Profarma contracted the services of UBS Pactual S.A. bank, on May 29, 2008, to be the market maker of its shares in order to promote their liquidity. • Profarma opened on July, 14, 2008 its first exclusive distribution center for the hospital and vaccine segment in São Paulo.
  • 3. Gross Revenues Evolution 3 In R$ MM 742.8 702.6 609.7 2Q07 1Q08 2Q08
  • 4. Gross Revenues Breakdown 4 In R$ MM (R$ Million) 2Q08 2Q07 Chg. % 1Q08 Chg.% Branded 519.7 404.7 28.4% 503.0 3.3% Generics 42.6 35.6 19.6% 34.0 25.4% OTC 131.7 120.2 9.5% 119.5 10.2% Health and Beauty Products 29.3 36.7 -20.1% 31.0 -5.5% Other 19.6 12.5 57.1% 15.1 29.3% Total 742.8 609.7 21.8% 702.6 5.7%
  • 5. Market Share (%) 5 11.5 11.8 11.8 10.7 9.6 9.6 9.3 2004 2005 2006 2007 2T07 1T08 2T08 Source: IMS
  • 6. Gross Profit and Revenues 6 from Services to Suppliers In R$ MM 10.8% and as % Net Revenues 10.7% 10.4% 10.5 7.4 7.0 55.7 58.9 50.0 2Q07 1Q08 2Q08 Gross Profit Revenues from Services to Suppliers Adjusted GP Margin (%)
  • 7. Operating Expenses 7 7.9% 7.9% In R$ MM and as % Net Revenues 7.8% 50.9 47.5 42.0 2Q07 1Q08 2Q08 EXPENSES: General and Administrative + Selling and Marketing + Logistics and Distribution
  • 8. Net Financial Expenses 8 In R$ MM 1.4% and as % Net Revenues 0.9% 0.5% 9.1 5.6 2.8 2Q07 1Q08 2Q08
  • 9. Net Income 9 1.6% In R$ MM and as % Net Revenues 1.0% 0.8% 8.3 6.6 5.0 2Q07 1Q08 2Q08
  • 10. Adjusted EBITDA and EBITDA Margin 10 In R$ MM 3.7% 3.7% and as % Net Revenues 3.1% 23.9 19.7 18.6 2Q07 1Q08 2Q08
  • 11. Cash Flow 11 (R$ Million) 2Q08 2Q07 Chg. % 1Q08 Chg. % Cash Flow (Used) / Generated in Operating Activities (24.0) (67.1) 64.3% 5.7 -521.1% Internal Cash Generation 16.7 17.1 -2.0% 14.8 13.4% Operating Assets Variation (40.7) (84.2) 51.7% (9.1) -349.1% Trade Note Receivable (11.6) (22.4) 48.4% 29.9 -138.7% Inventories (0.3) (41.3) 99.3% 19.3 -101.5% Suppliers (4.2) (8.9) 52.9% (49.4) 91.5% Other Items (24.6) (11.6) -112.6% (8.8) -179.8% Cash Flow (Used) in Investing Activities (3.1) (1.2) -154.1% (2.1) -45.6% Cash Flow (Used) / Generated by Financing Activities 38.5 (0.0) -154232.0% (34.4) -212.1% Net Increase (Decrease) in Cash 11.5 (68.4) -116.8% (30.8) -137.3%
  • 12. Cash Cycle 12 3Q06 4Q06 1Q07 2Q07 3Q07 4Q07 1Q08 2Q08 Cash Cycle - Days * 49.3 53.4 62.5 69.6 67.8 64.3 68.8 67.2 Accounts Receivable (1) 45.2 50.0 54.6 53.1 50.9 51.7 50.7 49.2 Inventories (2) 33.1 44.7 43.4 47.2 41.3 48.6 47.9 45.7 Accounts Payable (3) 29.0 41.3 35.6 30.7 24.5 36.0 29.8 27.7 *Average (1) Average of Gross Revenues in the Quarter (2) Average of COGS in the Quarter (3) Average of COGS in the Quarter
  • 13. Indebtedness 13 In R$ MM Net Debt (R$ MM) and Net Debt / Ebitda* 1.5 1.9 0.9 163.3 124.8 68.6 2Q07 1Q08 2Q08 * Ebitda = Accumulated last 12 months
  • 14. Capex 14 In R$ MM and as % Net Revenues 0.2% 0.5% 0.3% 3.1 2.1 1.2 2Q07 1Q08 2Q08
  • 15. Operating Indicators 15 Service Level Logistics E.P.M (units served / units requested) (Errors per Million) 92.8% 204.3 92.0% 91.2% 100.0 98.0 2Q07 1Q08 2Q08 2Q07 1Q08 2Q08
  • 16. Share Performance 16 196 * 100 pts basis on 25/oct/2006 191 186 181 176 171 166 161 164 156 151 146 141 136 139 131 126 121 116 111 110 106 101 96 25- 9- 24- 9- 24- 8- 23- 7- 22- 9- 24- 8- 23- 8- 23- 7- 22- 7- 22- 6- 21- 5- 20- 5- 20- 4- 19- 4- 19- 3- 18- 2- 17- 3- 18- 2- 17- 2- 17- 1- 16- 30- out nov nov dez dez jan jan fev fev mar mar abr abr mai mai jun jun jul jul ago ago set set out out nov nov dez dez jan jan fev fev mar mar abr abr mai mai jun jun jun Ibovespa IGC Profarma
  • 17. Analyst Coverage 17 Firm Analyst Recommendation João Carlos dos Santos - Alexandre Pizano 55 11 2188-4282 / 4316 / 4024 Merril Lynch Buy joaocarlos_santos@ml.com alexandre_pizano@ml.com Tufic Salem - Rafael Shin - Antonio Gonzalez 52 55 5283-8952 / 8969 / 3821 Credit Suisse tufic.salem@credit-suisse.com Buy rafael.shin@credit-suisse.com antonio.gonzalez@creditsuisse.com Alan Cardoso Prosper Corretora Fone: 55 21 2138-8465 Buy alan.cardoso@bancoprosper.com.br Renata Faber - Marcio Osako Fone: 55 11 5029-4542 / 4650 Hold Itau BBA renata.faber@itau.com.br marcio.osako@itau.com.br
  • 18. 18 IR Contacts: Max Fischer CFO and IRO Beatriz Diez IR Coordenator Phone.: 55 (21) 4009 0276 E-mail: ri@profarma.com.br www.profarma.com.br/ir